Other Information.
−Removed: None of the Company's directors and officers adopted, modified, or terminated a Rule 10b-1 trading arrangement or a non-Rule 10b5-1 trading arrangement during the Company's fiscal quarter ended June 30, 2024 (each as defined in Item 408 of Regulation S-K under the Securities Exchange Act of 1934, as amended).
+Added: None of the Company's directors and officers adopted, modified, or terminated a Rule 10b-1 trading arrangement or a non-Rule 10b5-1 trading arrangement during the Company's fiscal quarter ended December 31, 2024 (each as defined in Item 408 of Regulation S-K under the Securities Exchange Act of 1934, as amended).
EXHIBIT INDEX
−Removed: Amendment No.
−Removed: 3 to Edesa Biotech, Inc.
−Removed: 2019 Equity Incentive Compensation Plan (included as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on May 30, 2024, and incorporated herein by reference).
+Added: Amended and Restated Articles of Edesa Biotech, Inc.
+Added: (included as Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed on October 31, 2024, and incorporated herein by reference).
+Added: Amended Articles of Edesa Biotech, Inc.
+Added: (included as Exhibit 3.1 to the Company’s Current Report on Form 8-K, filed on February 13, 2025, and incorporated herein by reference).
+Added: Form of Warrant (included as Exhibit 4.1 to the Company’s Current Report on Form 8-K, filed on October 31, 2024, and incorporated herein by reference).
+Added: At The Market Offering Agreement, dated October 4, 2024, by and between Edesa Biotech, Inc.
+Added: Wainwright & Co., LLC (included as Exhibit 1.1 to the Company’s Current Report on Form 8-K, filed on October 4, 2024, and incorporated herein by reference).
+Added: Securities Purchase Agreement, dated October 30, 2024, between Edesa Biotech, Inc.
+Added: and Pardeep Nijhawan Medicine Professional Corporation (included as Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed on October 31, 2024, and incorporated herein by reference).
+Added: Form of Securities Purchase Agreement, dated February 12, 2025, between Edesa Biotech, Inc.
+Added: and the investors signatory thereto (included as Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed on February 13, 2025, and incorporated herein by reference).
+Added: Form of Investor Rights Agreement, dated February 12, 2025, between Edesa Biotech, Inc.
+Added: and the investors signatory thereto (included as Exhibit 10.2 to the Company’s Current Report on Form 8-K, filed on February 13, 2025, and incorporated herein by reference).
Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities and Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith).
13 unchanged sentences
under the Securities Act of 1933, as amended, or the Exchange Act of 1934, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
−Removed: Management contract or compensatory plan or arrangement.
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
+Added: February 14, 2025
EDESA BIOTECH, INC.
−Removed: August 9, 2024
/s/ Pardeep Nijhawan
1 unchanged sentence
(Principal Executive Officer)
−Removed: August 9, 2024
+Added: February 14, 2025
/s/ Stephen Lemieux
Stephen Lemieux, Chief Financial Officer
−Removed: (Principal Financial Officer)
+Added: (Principal Financial Officer and Duly Authorized Officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.